{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:07:24Z","timestamp":1790633244716,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cca.2023.117634","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T16:59:17Z","timestamp":1700499557000},"page":"117634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma"],"prefix":"10.1016","volume":"552","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9049-8719","authenticated-orcid":false,"given":"St\u00e9phane","family":"Muccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Descloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fedeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Mac\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Vialaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2023.117634_b0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.cca.2023.117634_b0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clinbiochem.2016.09.015","article-title":"Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood","volume":"51","author":"Murata","year":"2018","journal-title":"Clin. Biochem."},{"issue":"juin","key":"10.1016\/j.cca.2023.117634_b0015","first-page":"36","article-title":"Maladie r\u00e9siduelle dans le my\u00e9lome","volume":"supplement 2","author":"Avet-Loiseau","year":"2019","journal-title":"H\u00e9matologie"},{"key":"10.1016\/j.cca.2023.117634_b0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 myeloma patients in TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cca.2023.117634_b0025","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cca.2023.117634_b0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.73.1331","article-title":"Minimal residual disease negativity is a new end point of myeloma therapy","volume":"35","author":"Harousseau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2023.117634_b0035","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cca.2023.117634_b0040","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11899-021-00633-5","article-title":"MRD assessment in multiple myeloma: progress and challenges","volume":"16","author":"Bertamini","year":"2021","journal-title":"Curr Hematol Malig r."},{"key":"10.1016\/j.cca.2023.117634_b0045","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/clinchem\/hvab187","article-title":"Multiple myeloma minimal residual disease detection: targeted mass spectrometry in blood vs next-generation sequencing in bone marrow","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2023.117634_b0050","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-0649","article-title":"A personalized mass spectrometry-based assay to monitor M-protein in multiple myeloma patients (EasyM)","volume":"27","author":"Liyasova","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cca.2023.117634_b0055","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-023-00803-z","article-title":"Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry","volume":"13","author":"Noori","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cca.2023.117634_b0060","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bjh.17195","article-title":"Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma","volume":"193","author":"Abeykoon","year":"2021","journal-title":"Brit J Haematol."},{"key":"10.1016\/j.cca.2023.117634_b0065","doi-asserted-by":"crossref","first-page":"12446","DOI":"10.1182\/blood-2022-160249","article-title":"Comparison of the analytical performance of EXENT\u00ae, a mass spectrometry-based assessment of M-protein, to SPEP and NGS-based MRD in multiple myeloma patient samples","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cca.2023.117634_b0070","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmoldx.2020.04.002","article-title":"Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma","volume":"22","author":"Martins","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.cca.2023.117634_b0075","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinchem\/hvz041","article-title":"Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins","volume":"66","author":"Zajec","year":"2020","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2023.117634_b0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cca.2023.117634_b0085","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjh.18226","article-title":"The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: Where are we now and which questions remain unanswered?","volume":"198","author":"Giles","year":"2022","journal-title":"Brit J Haematol."},{"key":"10.1016\/j.cca.2023.117634_b0090","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s12185-022-03364-2","article-title":"Bringing mass spectrometry into the care of patients with multiple myeloma","volume":"115","author":"Murray","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.cca.2023.117634_b0095","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/hemato2040052","article-title":"Will mass spectrometry replace current techniques for both routine monitoring and MRD detection in multiple myeloma?","volume":"2","author":"Thoren","year":"2021","journal-title":"Hemato."},{"key":"10.1016\/j.cca.2023.117634_b0100","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1021\/pr5000544","article-title":"Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC\u2013MS\/MS","volume":"13","author":"Barnidge","year":"2014","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.cca.2023.117634_b0105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1373\/clinchem.2015.242651","article-title":"Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration","volume":"62","author":"Bergen","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2023.117634_b0110","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.jproteome.7b00890","article-title":"Development of a targeted mass-spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies","volume":"17","author":"Zajec","year":"2018","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.cca.2023.117634_b0115","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry","volume":"62","author":"Mills","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2023.117634_b0120","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.mayocp.2021.07.024","article-title":"Detection of plasma cell disorders by mass spectrometry: A comprehensive review of 19,523 cases","volume":"97","author":"Dasari","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.cca.2023.117634_b0125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymeth.2015.04.020","article-title":"Detecting monoclonal immunoglobulins in human serum using mass spectrometry","volume":"81","author":"Mills","year":"2015","journal-title":"Methods"},{"key":"10.1016\/j.cca.2023.117634_b0130","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1021\/acs.analchem.0c03357","article-title":"High-throughput therapeutic antibody interference-free high-resolution mass spectrometry assay for monitoring M-proteins in multiple myeloma","volume":"93","author":"Santockyte","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2023.117634_b0135","doi-asserted-by":"crossref","first-page":"15236","DOI":"10.1021\/acs.analchem.1c03410","article-title":"Validated method based on immunocapture and liquid chromatography coupled to high-resolution mass spectrometry to eliminate isatuximab interference with M-protein measurement in serum","volume":"93","author":"Muccio","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2023.117634_b0140","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1021\/acs.jproteome.0c01022","article-title":"Mass spectrometry provides a highly sensitive noninvasive means of sequencing and tracking M-protein in the blood of multiple myeloma patients","volume":"20","author":"McDonald","year":"2021","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.cca.2023.117634_b0145","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1373\/clinchem.2015.253781","article-title":"Screening method for M-Proteins in serum using nanobody enrichment coupled to MALDI-TOF mass spectrometry","volume":"62","author":"Kohlhagen","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2023.117634_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","article-title":"Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma","volume":"13","author":"Mai","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cca.2023.117634_b0155","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.seminhematol.2018.02.008","article-title":"Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease","volume":"55","author":"Thoren","year":"2018","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.cca.2023.117634_b0160","doi-asserted-by":"crossref","unstructured":"M. Attal, P.G. Richardson, S.V. Rajkumar, J. San-Miguel, M. Beksac, I. Spicka, X. Leleu, F. Schjesvold, P. Moreau, M.A. Dimopoulos, J.S.-Y. Huang, J. Minarik, M. Cavo, H.M. Prince, S. Mac\u00e9, K.P. Corzo, F. Campana, S. Le-Guennec, F. Dubin, K.C. Anderson, I.-M. study group, M. Attal, P.G. Richardson, V. Rajkumar, J. San-Miguel, M. Beksac, I. Spicka, X. Leleu, F. Schjesvold, P. Moreau, M.A. Dimopoulos, J.S.-Y. Huang, J. Minarik, M. Cavo, H.M. Prince, S. Mac\u00e9, K.P. Corzo, F. Campana, S. Le-Guennec, F. Dubin, K.C. Anderson, S. Harrison, W. Janowski, I. Kerridge, A. Spencer, M. Delforge, K. Fostier, P. Vlummens, K.L. Wu, R. Leblanc, M. Pavic, M. Sebag, R. Hajek, V. Maisnar, L. Pour, H. Gregersen, L. Benbouker, D. Caillot, M. Escoffre-Barbe, T. Facon, L. Frenzel, C. Hulin, L. Karlin, B. Kolb, B. Pegourie, A. Perrot, M. Tiab, L. Vincent, D. Niederwieser, A. Anagnostopoulos, S. Delimpasi, M.-C. Kyrtsonis, A. Symeonidis, A. Illes, G. Mikala, Z. Nagy, S. Bringen, P. Corradini, C. Fabio, R. Lemoli, A. Liberati, C. Nozzoli, R. Zambello, S. Iida, T. Ikeda, S. Iyama, M. Matsumoto, C. Shimazaki, K. Sunami, K. Suzuki, M. Uchiyama, Y. Koh, K. Kim, J.H. Lee, C.-K. Min, H. Blacklock, H. Goodman, A. Neylon, D. Simpson, S. Grosicki, A. Jurczyszyn, A. Walter-Croneck, K. Warzocha, L. Araujo, C. Moreira, V. Doronin, L. Mendeleeva, V. Vorobyev, A. Vranovsky, A. Alegre, M. Gironella, M.S.G. Perez, C. Montes, E. Ocio, P. Rodriguez, M. Hardling, B. Lauri, M.-C. Wang, S.-P. Yeh, M. Arat, F. Demirkan, Z. Gulbas, S.K. Besisik, I. Karadogan, T. Tuglular, A. Unal, F. Vural, J. Sive, M. Streetly, K. Yong, J. Tache, Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study, Lancet. 394 (2019) 2096\u20132107. doi: 10.1016\/s0140-6736(19)32556-5.","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"10.1016\/j.cca.2023.117634_b0165","doi-asserted-by":"crossref","unstructured":"P. Moreau, M.-A. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. \u0160pi\u010dka, R. Baker, K. Kim, G. Martinez, C.-K. Min, L. Pour, X. Leleu, A. Oriol, Y. Koh, K. Suzuki, M.-L. Risse, G. Asset, S. Mac\u00e9, T. Martin, I. study group, P. Moreau, M.-A. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, R. Baker, K. Kihyun, G. Martinez, M. Chang-Ki, L. Pour, X. Leleu, A. Oriol, K. Youngil, K. Suzuki, T. Martin, H. Quach, A. Lim, H. Crowther, H. Sia, C. Hulin, M. Mohty, G. Mikala, Z. Nagy, M.R. Segura, L. Rosinol, M. Yagci, M. Turgut, M. Garg, G. Parmar, B. Augustson, N. Castro, E. Crusoe, T. Pika, S. Delimpasi, K. Ishizawa, A. George, T. Konstantinova, J.D.L. Rubia, K. Sung-Hyun, A. Maiolino, A. Reiman, R. LeBlanc, S. Ito, J. Tanaka, A. Luchinin, I. Kryuchkova, J. Martinez, J. Shustik, L. Karlin, A. Symeonidis, M. Egyed, M. Petrini, M. Cavo, M. Uchiyama, H. Blacklock, M. Arat, J. Griffin, H. Hunter, T. Buck, A. Anagnostopoulos, K. Konstantopoulos, T. Masszi, S. Bringhen, B. Gamberi, Y. Kawano, K.J. Seok, H. Ozdogu, F. Ozkalemkas, Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial, Lancet. 397 (2021) 2361\u20132371. Doi: 10.1016\/s0140-6736(21)00592-4.","DOI":"10.1016\/S0140-6736(21)00592-4"},{"key":"10.1016\/j.cca.2023.117634_b0170","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1182\/bloodadvances.2021006713","article-title":"Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma","volume":"6","author":"Martin","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2023.117634_b0175","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41408-021-00562-9","article-title":"Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma","volume":"11","author":"Hulin","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cca.2023.117634_b0180","doi-asserted-by":"crossref","unstructured":"E.M. Ocio, A. Perrot, P. Bories, J.F. San-Miguel, I.W. Blau, L. Karlin, J. Martinez-Lopez, S.-Y. Wang, S. Bringhen, M. Marcatti, M.-V. Mateos, P. Rodriguez-Otero, S. Oliva, A. Nogai, N.L. Roux, L. Dong, S. Mac\u00e9, M. Gassiot, T. Fitzmaurice, C. Oprea, P. Moreau, Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation, Leukemia. (2023) 1\u20139. Doi: 10.1038\/s41375-023-01936-7.","DOI":"10.1038\/s41375-023-01936-7"},{"key":"10.1016\/j.cca.2023.117634_b0185","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1373\/jalm.2018.026476","article-title":"Distinguishing drug from disease by use of the hydrashift 2\/4 daratumumab assay","volume":"3","author":"Thoren","year":"2019","journal-title":"The J. Appl. Lab. Med."},{"key":"10.1016\/j.cca.2023.117634_b0190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-136613","article-title":"Development of a Hydrashift 2\/4 isatuximab assay to mitigate interference with monoclonal protein detection on immunofixation electrophoresis in vitro diagnostic tests in multiple myeloma","volume":"136","author":"Finn","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cca.2023.117634_b0195","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ajh.24772","article-title":"The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic","volume":"92","author":"Milani","year":"2017","journal-title":"Am. J. Hematol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123004369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123004369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:11:05Z","timestamp":1757862665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898123004369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":39,"alternative-id":["S0009898123004369"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2023.117634","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2023.117634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117634"}}